![Immuno | Free Full-Text | LDH Isotyping for Checkpoint Inhibitor Response Prediction in Patients with Metastatic Melanoma Immuno | Free Full-Text | LDH Isotyping for Checkpoint Inhibitor Response Prediction in Patients with Metastatic Melanoma](https://pub.mdpi-res.com/immuno/immuno-01-00005/article_deploy/html/images/immuno-01-00005-g001.png?1628120487)
Immuno | Free Full-Text | LDH Isotyping for Checkpoint Inhibitor Response Prediction in Patients with Metastatic Melanoma
![Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis | British Journal of Cancer Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis | British Journal of Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fbjc.2012.306/MediaObjects/41416_2012_Article_BFbjc2012306_Fig3_HTML.jpg)
Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis | British Journal of Cancer
![Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins | Modern Pathology Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins | Modern Pathology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fmodpathol.2009.129/MediaObjects/41379_2010_Article_BFmodpathol2009129_Fig1_HTML.jpg)
Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins | Modern Pathology
![Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors | Targeted Oncology Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors | Targeted Oncology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11523-021-00792-8/MediaObjects/11523_2021_792_Fig2_HTML.png)
Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors | Targeted Oncology
![Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors | Targeted Oncology Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors | Targeted Oncology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11523-021-00792-8/MediaObjects/11523_2021_792_Fig5_HTML.png)
Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors | Targeted Oncology
![Cancers | Free Full-Text | Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH? Cancers | Free Full-Text | Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?](https://www.mdpi.com/cancers/cancers-11-01940/article_deploy/html/images/cancers-11-01940-g003b.png)
Cancers | Free Full-Text | Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?
![Serum LDH does not associate with TMA markers evaluated as continuous... | Download Scientific Diagram Serum LDH does not associate with TMA markers evaluated as continuous... | Download Scientific Diagram](https://www.researchgate.net/publication/345317489/figure/fig3/AS:11431281179296157@1691171080808/Serum-LDH-does-not-associate-with-TMA-markers-evaluated-as-continuous-variables-in.png)
Serum LDH does not associate with TMA markers evaluated as continuous... | Download Scientific Diagram
![Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins | Modern Pathology Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins | Modern Pathology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fmodpathol.2009.129/MediaObjects/41379_2010_Article_BFmodpathol2009129_Fig4_HTML.gif)
Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins | Modern Pathology
![Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker - Fischer - 2020 - Cancer Medicine - Wiley Online Library Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker - Fischer - 2020 - Cancer Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/ce10b59c-8275-4957-ae2a-5d23515ff5c1/cam43474-fig-0005-m.jpg)
Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker - Fischer - 2020 - Cancer Medicine - Wiley Online Library
![Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins - ScienceDirect Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S089339522202779X-gr5.jpg)
Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins - ScienceDirect
![Immuno | Free Full-Text | LDH Isotyping for Checkpoint Inhibitor Response Prediction in Patients with Metastatic Melanoma Immuno | Free Full-Text | LDH Isotyping for Checkpoint Inhibitor Response Prediction in Patients with Metastatic Melanoma](https://pub.mdpi-res.com/immuno/immuno-01-00005/article_deploy/html/images/immuno-01-00005-ag.png?1628120487)
Immuno | Free Full-Text | LDH Isotyping for Checkpoint Inhibitor Response Prediction in Patients with Metastatic Melanoma
![Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis | British Journal of Cancer Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis | British Journal of Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fbjc.2012.306/MediaObjects/41416_2012_Article_BFbjc2012306_Fig2_HTML.jpg)
Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis | British Journal of Cancer
![Table 1 from Serum Lactate Dehydrogenase (LDH) Activity in Children with Malignant Diseases | Semantic Scholar Table 1 from Serum Lactate Dehydrogenase (LDH) Activity in Children with Malignant Diseases | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/90e204f332e8ec58f459c333226f0fd14fecd57b/3-Table2-1.png)
Table 1 from Serum Lactate Dehydrogenase (LDH) Activity in Children with Malignant Diseases | Semantic Scholar
![Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors | Targeted Oncology Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors | Targeted Oncology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11523-021-00792-8/MediaObjects/11523_2021_792_Fig4_HTML.png)
Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors | Targeted Oncology
![Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker - Fischer - 2020 - Cancer Medicine - Wiley Online Library Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker - Fischer - 2020 - Cancer Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/9e78cba8-3293-4cb7-ab09-006bd1e56530/cam43474-toc-0001-m.jpg?trick=1699087953036)
Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker - Fischer - 2020 - Cancer Medicine - Wiley Online Library
![Cancers | Free Full-Text | Blockade of Lactate Dehydrogenase-A (LDH-A) Improves Efficacy of Anti-Programmed Cell Death-1 (PD-1) Therapy in Melanoma Cancers | Free Full-Text | Blockade of Lactate Dehydrogenase-A (LDH-A) Improves Efficacy of Anti-Programmed Cell Death-1 (PD-1) Therapy in Melanoma](https://www.mdpi.com/cancers/cancers-11-00450/article_deploy/html/images/cancers-11-00450-g001.png)